| Literature DB >> 18587555 |
F Vom Dorp1, C Börgermann, A Rose, M Becker, H Rübben.
Abstract
The current therapy concept for metastatic bladder cancer is chemotherapy with gemcitabine and cisplatin as the first line protocol. Within the last 20 years no real progress could be achieved; the median survival is 14 months, though many different protocols have been tested. Expression analyses of growth factor receptors in human tumor tissue showed that expression of certain receptors is correlated with a severe clinical course.For many of these growth factor receptors pharmacological inhibitors are available in order to perform targeted therapy. The following review gives a survey of current studies on targeted therapy of metastatic bladder carcinoma.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18587555 DOI: 10.1007/s00120-008-1747-9
Source DB: PubMed Journal: Urologe A ISSN: 0340-2592 Impact factor: 0.639